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INTRODUCTION
Atrial fibrillation (AF) is the most common arrhythmia in clini-
cal practice and causes significant morbidity and mortality.1 
Although the use of radiofrequency catheter ablation (RFCA) 
is increasing around the world,2 analysis of pre-procedural 
characteristics that stratify for procedural efficacy and safety 
might be helpful, given the cost and potential complication of 
this procedure.3 Recent studies have demonstrated that early 
recurrence of AF (ERAF) after catheter ablation might be asso-
ciated with a worse rhythm outcome during long-term follow-
up, although the proportion of clinical recurrence of AF three 
months after RFCA varies gradually.4 The pathophysiology of 
ERAF remains unclear; however, pro-inflammatory effects af-
ter catheter ablation may play an important role in ERAF.5 Ni-
tric oxide (NO) is one of many essential factors suppressing 
arrhythmia through a cGMP-mediated modulation of cardiac 
autonomic nerve activity or atrial electrical remodeling.6 Sever-
al studies suggest that NO levels and bioavailability are markedly 
reduced in the atria during AF.6,7 One clinically relevant eNOS 
variant is the missense G894T variant (rs1799983) in exon 7. 
This mutation corresponds to a Glu-Asp substitution (Glu-
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298Asp).8 The rs1799983 variant has been reported to be associ-
ated with reduced basal NO production9 and ischemic stroke.10 
Some of eNOS3 gene polymorphisms were reported to be asso-
ciated with predisposition to AF,11,12 but other single nucleotide 
polymorphisms (SNPs) of the same gene were not. So, there 
still remains some controversy regarding this finding.13 The 
present study explored the relationship between eNOS3 SNPs 
and the recurrence of AF after catheter ablation. 
MATERIALS AND METHODS
Study population
The study protocol was approved by the Institutional Review 
Board of the Yonsei University Health System and all patients 
provided written informed consent. Participants included 500 
consecutive Korean patients with AF who underwent RFCA 
and 500 age, gender-matched healthy control provided by Na-
tional Biobank of Korea (KOBB-2012-00).14 Exclusion criteria 
were as follows: 1) permanent AF refractory to electrical car-
dioversion; 2) left atrial (LA) size >55 mm as measured by echo-
cardiogram; 3) AF with valvular disease >grade 2; 4) any struc-
tural heart disease other than left ventricular hypertrophy; 5) 
residual coronary artery stenosis >75%; and 6) prior AF ablation 
or maze surgery. Three-dimensional (3D) spiral computerized 
tomography (CT) scans (64 Channel, Light Speed Volume CT, 
Philips Brilliance 63, Eindhoven, the Netherlands) were per-
formed to visually define the pulmonary vein (PV) anatomy. 
Using trans-esophageal echocardiography, we ensured that 
no LA thrombus was present. All antiarrhythmic drugs were 
discontinued for at least five half-lives of the respective drugs. 
Amiodarone was discontinued at least four weeks prior to the 
procedure. Anticoagulation therapy was performed before 
catheter ablation.
Electrophysiologic mapping and radiofrequency (RF) 
catheter ablation
Intracardiac electrograms were recorded using the Prucka 
CardioLabTM electrophysiology system (General Electric 
Health Care System Inc., Milwaukee, WI, USA), and catheter 
ablation was performed in all patients using 3D electroana-
tomical mapping (St. Jude Medical Inc., Minnetonka, MN, USA) 
merged with 3D spiral CT. If the initial recording identified a 
sinus rhythm, an LA 3D electroanatomical voltage map was 
generated during atrial pacing by obtaining contact bipolar 
electrograms from 350–400 points on the LA endocardium. 
Color-coded voltage maps were generated by recording bipo-
lar electrograms and measuring peak-to-peak voltage during 
high right atrial pacing with a cycle length of 500 ms as previ-
ously described.15-17 We used an open irrigated-tip catheter 
(Celsius, Johnson & Johnson Inc.; Diamond Bar, CA, USA; irri-
gation flow rate 20 to 30 mL/min; 30 W; 47°C) to deliver RF en-
ergy for ablation (Stockert generator, Biosense Webster Inc.; Di-
amond Bar, CA, USA). We generally performed RFCA in sinus 
rhythm after electrical cardioversion. However, if sinus rhythm 
could not be maintained due to immediate recurrence of AF, 
RFCA was performed while in AF. All patients initially under-
went circumferential PV isolation and bi-directional block of 
the cavo-tricuspid isthmus. For patients with paroxysmal AF, 
additional linear ablation or complex fractionated atrial elec-
trogram (CFAE) ablation guided by 3D-CFAE-CL map18 was 
conducted depending on the operator’s decision. In patients 
with persistent AF, circumferential PV isolation, cavo-tricuspid 
isthmus block, and roof line, posterior inferior line, and ante-
rior line19 were performed as a standard lesion set. If AF per-
sisted, CFAE ablation was done depending on the operator’s 
decision. Most of procedures were conducted during sinus 
rhythm after cardioversion to generate voltage map. However, 
if AF persisted despite administration of the aforementioned 
ablation protocols, procedures were stopped after internal car-
dioversion. Procedural end-point was defined when there was 
no immediate recurrence of AF after cardioversion by isopro-
terenol infusion (5–20 μg/min). If non-PV foci were identified 
in 10.9% under isoproterenol, they were all ablated.
Post-ablation follow-up
All patients were followed in the absence of anti-arrhythmic 
medications after RFCA. Patients were asked to visit an outpa-
tient clinic at 1, 3, 6, and 12 months after RFCA and then every 
6 months thereafter for follow-up. Electrocardiography (ECG) 
was performed at each visit and whenever the patient report-
ed palpitations. A Holter ECG (24- or 48-hour) and/or event re-
corder was performed on patient at every six-month follow-up 
and whenever the patient complained of symptoms for at least 
two years according to 2012 ACC/AHA/ESC expert consensus 
guideline for AF management.20 We defined recurrence of AF 
as any episode of AF or atrial tachycardia of at least 30 sec in 
duration.21 We did not use routine anti-inflammatory drug af-
ter procedure. If the patient complained symptomatic arrhyth-
mia within 3rd month of procedure, we tried to document it 
by Holter ECG or event recorder depending on the frequency 
and duration of symptom. If AF was found on ECG within the 
three-month blanking period during follow-up, the patient was 
diagnosed with ERAF, and any AF recurrence thereafter was 
diagnosed as clinical recurrence.21 For the patients with symp-
tomatic ERAF, we prescribed anti-arrhythmic drug. However, 
we stopped antiarrhythmic drug in these patients, if there was 
no AF in 3rd month Holter ECG.
 
Off-line analyses of color-coded 3D maps 
and CT images
We analyzed color-coded voltage maps of both anterior-poste-
rior and posterior-anterior views. Percent of each color area 
was calculated by customized software (Image Pro) and refer-
enced with color scale bars. PVs were not included in the anal-
ysis. Low voltage areas, defined as LA voltage <0.2 mV, were 
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colored gray, and high voltage areas (>5.0 mV) were colored 
purple.
Biochemical analyses
Plasma levels of high sensitivity C-reactive protein (hsCRP) 
was quantified with a commercially available enzyme-linked 
immunosorbent assay (R&D Systems, Minneapolis, MN, USA) 
method in peripheral blood samples taken just before the 
procedure.
Genotyping of  rs1799983 in whole blood
eNOS is an enzyme that catalyzes the formation of NO from L-
arginine. Several polymorphisms have been described. 
rs1799983 G894T is evaluated in the present study.22 Genotyp-
ing of rs1799983 was performed using a validated TaqMan as-
say (Applied Biosystems, Life Technologies, Carlsbad, CA, 
USA). Polymerase chain reaction (PCR) was performed using 
0.9 μm of forward and reverse primers, 0.2 μm of fluorescein 
amidite and VIC minor groove binding sequence-specific 
probes. PCR constituents were as follows: 3 ng of DNA, 5.0 mM 
MgCl2, and 1x TaqMan Universal PCR Master Mix containing 
AmpliTaq Gold DNA polymerase in a 5.5-μL reaction volume. 
Both the SNPs had a call rate of >99%. 
Statistical analysis
Statistical analysis was performed using the Statistical Pack-
age for Social Sciences software for Windows version 18.0 (SPSS 
Inc., Chicago, IL, USA). A chi-square test was used to test the 
deviation of genotype distribution from Hardy-Weinberg equi-
librium. Genotype distribution and allelic frequencies in pa-
tients with and without AF recurrence were compared using a 
chi-square test. The strength of the association between gene 
trait and ERAF was determined by calculating an odds ratio 
and 95% confidence interval. p<0.05 was considered signifi-
cant.
RESULTS
Frequency of rs1799983 variant allele in patients with 
AF vs. controls
The baseline characteristics of study population are shown in 
Table 1. Participants included 500 consecutive Korean pa-
tients with AF (77% males, 56±11 years old) who underwent 
RFCA and 500 age, gender-matched healthy control without 
ECG documented AF, provided by National Biobank of Korea 
(KOBB-2012-00). Among the AF patients, 68% had paroxys-
mal and 32% had persistent AF. A mean of 1.9±1.3 antiarrhyth-
mic drugs had been used to treat the AF patients prior to 
RFCA. Table 2 shows the genotype distribution and allele fre-
quencies of the eNOS polymorphisms. Variant frequency did 
not deviate significantly from Hardy-Weinberg equilibrium. 
There were no significant differences in the genotype and al-
lele frequencies between the patient and control group.
Characteristics of eNOS3 gene (rs1799983) variants and 
AF recurrence
Table 3 summarizes the differences between AF patients with 
rs1799983 variants and those without variants. There were no 
significant differences in general clinical features and the de-
gree of LA electro-anatomical remodeling between patients 
with and without the rs1799983 variant (T). In addition, serum 
hsCRP levels were not significantly higher in patients with the 
rs1799983 variant. Interestingly, the frequency of associated 
stroke/transient ischemic attack and coronary artery disease 
was significantly higher in patients with the rs1799983 variant 
(p=0.004). Statin utilization was also significantly higher in pa-
tients with the rs1799983 variant (p=0.010). ERAF (within 3 
months post-RFCA) was observed in 31.8%, whereas clinical 
recurrence of AF (after 3 months post-RFCA) occurred in 24.8% 
of the patients during mean follow-up of 17±8 months. The 
clinical recurrence rate after 3 month post-RFCA was not differ-
ent in patients with rs1799983 variant and in those without 
(p=0.907). However, ERAF was more frequent in patients with 
the variant allele of the rs1799983 than in those without (42.2% 
vs. 29.8%, p=0.027). In addition, ERAF occurred significantly 
earlier in the carriers of the variant allele (mean early recur-
Table 1. Baseline Characteristics of AF Patients
Variables
AF
(n=500)
Control
(n=500)
p value
Age (yrs) 56±11 55±12 0.166
Male (%) 77 77 1.000
Paroxysmal AF (%) 68 NA NA
CHADS2 Score 0.84±1.01 NA NA
CHF (%) 3.0 NA NA
Hypertension (%) 45 NA NA
Age≥75 (%) 3.6 NA NA
Diabetes (%) 11.7 NA NA
Stroke/TIA (%) 10.5 NA NA
CAD (%) 12.2 NA NA
Mean LA size (mm) 41.7±6.3 NA NA
LVEF (%) 63.7±8.1 NA NA
NA, not applicable; AF, atrial fibrillation; CHF, congestive heart failure; TIA, 
transient ischemic attack; LA, left atrium; LVEF, left ventricular ejection frac-
tion; CAD, coronary artery disease.
Table 2. Genotype Distribution and Allele Frequencies of eNOS Polymor-
phisms
Genotype/ 
allele
Patients
(n=500)
Control
(n=500)
p value
GG* 416 (83.2) 419 (83.8) 0.798
GT* 81 (16.2) 80 (16.0) 0.931
TT* 3 (0.6) 1 (0.2) 0.316
T† 87 (8.7) 82 (8.2) 0.682
*Genotype distribution, †Allele frequency in additive model.
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rence days, 11±16 days vs. 20±25 days, p=0.016) (Fig. 1).
In the sub-analysis for Persistent AF, early and clinical recur-
rence rates were 59.3% and 26.9% in the rs1799983 variants, and 
40.0% and 45.1% in non-variant group, respectively. However, 
early (p=0.066) and clinical recurrence rates (p=0.087) did not 
reach to the statistical difference. Among 124 patients with clin-
ical recurrence, we tried anti-arrhythmic medication first. If re-
curred AF was not controlled by antiarrhythmic drug, we con-
ducted redo-ablation in 46 patients (4.8% in rs1799983 variant 
group vs. 10.1% in non-variant group, p=0.084). Early recur-
rences were observed in 1 out of 4 patients in variant group and 
14 out of 42 patients in non-variant group after redo-proce-
dure. None of 4 patients in variant group and 15 out of 42 pa-
tients in non-variant group recurred after 3rd month of redo-
ablation. 
Characteristics and predictors of ERAF after RFCA
Table 4 compares characteristics of AF patients with and with-
out early recurrence. Patients with early recurrence were more 
likely to have persistent AF (44.4% vs. 27.1%, p<0.001) and had 
larger left atria (p=0.011) compared to those without early re-
currence. LA endocardial voltages were significantly lower in 
patients with early recurrence than in those without (p=0.025). 
Patients with early recurrence were more likely to be taking an 
angiotensin converting enzyme inhibitor or an angiotensin II 
receptor blocker than those without (p=0.020). In contrast, 
procedure time (p<0.001) and ablation time (p<0.001) were 
significantly longer in patients with early recurrence.
In a univariate analysis, persistent AF, larger LA size, and 
presence of the rs1799983 variant were associated with ERAF 
after RFCA. Multivariate analysis showed that the rs1799983 
variant (OR 1.75, 95% CI 1.07–2.86, p=0.026) and persistent AF 
(OR 1.91, 95% CI 1.27–2.94, p=0.003) were independent pre-
dictors of ERAF (Table 5).
Table 3. Comparison of AF Patients with and without the rs1799983 
Variant
Clinical parameters
AF patients 
with 
rs1799983 
variant (n=84)
AF patients 
without 
rs1799983 
variant (n=416)
p value
Age 58±11 56±11
Male, % 73.8 77.6
Paroxysmal AF, % 67.3 67.9
BSA, m2 1.81±0.18 1.82±0.17
BMI, kg/m2 24.7±2.8 24.8±2.8
CHADS2 Score, % 0.93±1.12 0.82±0.98
CHF 0.0 3.6
Hypertension 44.0 45.0
Age≥75 6.0 3.0
DM 14.3 11.3
Stroke/TIA 14.3 9.1
CAD, % 16.7 11.3
Stroke/TIA or CAD 31.0 17.3 0.004
Echo findings
LA size, mm 41.7±5.7 41.7±6.3
LVEF, % 65.0±7.3 63.4±8.2
E/E’ 10.6±4.0 10.3±4.4
LA voltage, mV
Mean LA 1.22±0.63 1.19±0.57
Venous LA 1.10±0.89 0.95±0.77
LA appendage 2.36±1.40 2.34±1.36
Anterior LA 1.09±0.63 1.05±0.54
Conduction velocity, m/sec
Anterior 0.56±0.29 0.61±0.29
Posterior 0.57±0.35 0.67±0.48
Medications, %
ACEi/ARB 27.7 30.1
Statin 30.1 17.8 0.010
Biomarker
hsCRP, mg/L 2.33±4.94 2.06±4.36
Procedure, min
Procedure time 191±38 194±50
Fluoroscopic time 47±14 50±30
Ablation time 87±24 87±27
Recurrence, %
Early recurrence 42.2 29.8 0.027
Clinical recurrence 25.3 24.7
CAD, coronary artery disease; ACEi, angiotensin converting enzyme inhibitor; 
ARB, angiotensin II receptor blocker; AF, atrial fibrillation; BSA, body surface 
area; CHF, congestive heart failure; DM, diabetes mellitus; TIA, transient isch-
emic attack; LA, left atrium; LVEF, left ventricular ejection fraction; hsCRP, high 
sensitivity C-reactive protein; BMI, body mass index.
Fig. 1. Kaplan-Meier curves of AF free survival between patients with 
and without the rs1799983 variant within 3 months after RFCA of AF. AF, 
atrial fibrillation; RFCA, radiofrequency catheter ablation.
1.0
0.8
0.6
0.4
0.2
0.0
rs1799938 non-variant
rs1799938 variant
Log rank p=0.015
Days
 0 20 40 60 80 100
AF
 fr
ee
 su
rv
iva
l
http://dx.doi.org/10.3349/ymj.2015.56.5.12441248
eNOS3 Gene Polymorphism and Recurrence of AF
DISCUSSION
We found that the eNOS SNP rs1799983 is associated with 
ERAF after catheter ablation. Although the frequency of the 
rs1799983 risk allele (T) is similar among cases and controls, 
risk allele carriers were more likely to have coronary artery 
disease, stroke and ERAF within 3 month post-RFCA.
eNOS, cardiovascular disease/stroke, and AF
The eNOS gene SNPs, rs1799983 has been reported to be as-
sociated with hypertension23 and ischemic stroke.24 In addi-
tion, Park, et al.25 reported the association of the rs1799983 gene 
polymorphism with acute coronary syndrome in Korean pa-
tients. In the present study, patients with the rs1799983 vari-
ant were found to be more likely to have coronary artery disease 
or stroke which is consistent with previous studies.
AF has been associated with a marked decrease in NOS ex-
pression and NO bioavailability in the LA.7 These data indi-
cate that laminar blood flow in sinus rhythm and the cyclic 
stretch of atrial endocardial cells may act as a stimulus for 
maintaining normal endocardial expression and function of 
NOS. It is likely that loss of this important antithrombotic en-
zyme contributes to the thromboembolic phenomena com-
monly observed in AF. The association of eNOS3 gene poly-
morphism, rs1799983, with AF has been investigated by several 
studies. Bedi, et al.11 reported that rs1799983 TT genotype was 
associated with AF in patients with congestive heart failure. In 
contrast, Fatini, et al.11,12 and Gensini, et al.13 did not find rela-
tionship between rs1799983 polymorphism and AF, which is 
consistent with the current study. Although we did not find a 
difference in the frequency of the rs1799983 variant between 
the AF and control groups, carriers of the rs1799983 variant al-
lele appeared to show a different clinical course after catheter 
ablation of AF due to decreased NO activity.
ERAF and rs1799983 variant
Although the mechanism of ERAF after RFCA remains unclear, 
there are potential explanations. First, post-RFCA inflammation 
Table 4. Comparison of AF Patients with and without Early Recurrence 
of Atrial Fibrillation
Clinical parameter
AF patients 
with 
ERAF (n=167)
AF patients 
without 
ERAF (n=336)
p value
Age 58±10 56±12
Male, % 78.1 76.7
Paroxysmal AF, % 55.6 72.9 <0.001
BSA, m2 1.82±0.16 1.82±0.18
BMI, kg/m2 24.6±2.7 24.8±2.8
CHADS2 Score, % 0.76±0.84 0.88±1.08
CHF 1.9 3.5
Hypertension 46.9 44.3
Age≥75 1.9 4.4
DM 9.4 12.8
Stroke/TIA 8.1 11.1
CAD, % 13.1 12.0
Echo findings
LA size, mm 42.8±6.4 41.2±6.2 0.011
LVEF, % 63.3±7.8 63.8±8.3
E/E’ 10.5±4.3 10.3±4.3
LA voltage, mV
Mean LA 1.09±0.58 1.25±0.59 0.025
Venous LA 0.88±0.74 1.03±0.82
LA Appendage 2.05±1.29 2.47±1.39 0.012
Anterior LA 0.97±0.54 1.10±0.55 0.043
Conduction velocity, m/sec
Anterior 0.59±0.31 0.61±0.28
Posterior 0.62±0.38 0.66±0.38
Medications, %
ACEi/ARB 37.1 26.9 0.020
Statin 17.6 21.3
Biomarker
hsCRP, mg/L 2.47±6.87 1.92±2.63
Procedure, min
Procedure time 211±63 185±37 <0.001
Fluoroscopic time 53±19 48±32
Ablation time 96±29 83±24 <0.001
rs1799983 variant, % 22.0 13.8 0.027
CAD, coronary artery disease; ACEi, angiotensin converting enzyme inhibitor; 
ARB, angiotensin II receptor blocker; AF, atrial fibrillation; BSA, body surface 
area; BMI, body mass index; CHF, congestive heart failure; DM, diabetes 
mellitus; TIA, transient ischemic attack; LA, left atrium; LVEF, left ventricular 
ejection fraction; hsCRP, high sensitivity C-reactive protein; ERAF, early recur-
rence of AF.
Table 5. Univariate and Multivariate Analyses for Early AF Recurrence
OR 95% CI p value
Univariate analysis
Age 1.01 0.99–1.03
Male gender 1.06 0.68–1.66
Persistent AF 2.14 1.45–3.18 <0.001
Hypertension 1.10 0.76–1.60
DM 0.79 0.44–1.44
CHADS2 0.91 0.75–1.10
LA size 1.04 1.01–1.07 0.012
LVEF 0.99 0.98–1.02
E/E’ 1.01 0.97–1.06
Mean LA voltage 0.61 0.39–0.94 0.026
ACEi/ARB 1.60 1.07–2.39 0.021
hsCRP 1.03 0.98–1.07
rs1799983 variant (T) 1.72 1.06–2.79 0.028
Multivariate analysis
Persistent AF 1.91 1.27–2.94 0.038
rs1799983 variant (T) 1.75 1.07–2.86 0.040
AF, atrial fibrillation; DM, diabetes mellitus; LA, left atrium; LVEF, left ventric-
ular ejection fraction; ACEi, angiotensin converting enzyme inhibitor; ARB, 
angiotensin II receptor blocker; hsCRP, high sensitivity C-reactive protein.
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is related to electrical instability. An acute inflammatory re-
sponse is associated with extensive tissue damage involved in 
extensive AF catheter ablation, and the time course of the pre-
sumed resolution of this inflammation correlates well with 
spontaneous arrhythmia resolution.26 This inflammation is suf-
ficient to facilitate the initiation of atrial arrhythmias.27 In this 
study, ERAF was higher in patients with the rs1799983 variant 
allele, and reduced NO availability in genetic variants may con-
tribute to impaired resolution of inflammation after extensive 
RFCA. However, we did not find a relationship between rs1799 
983 variants and plasma levels of hsCRP in this study. This may 
be because plasma levels of hsCRP are influenced by multiple 
factors including the degree of electroanatomical remodeling 
of the atrium28 as well as persistence of AF.29
Alternative explanation for ERAF is the recovery of electrical 
conduction at the ablation sites. This mechanism may explain 
the fact that 40% of patients with ERAF extend to clinical recur-
rence of AF 3 months after RFCA. ERAF has been known to be 
an independent predictor for clinical recurrence after RFCA.4 
Remaining 60% of patients with ERAF had no clinical recur-
rence after 3 months. Therefore, the mechanism of ERAF in pa-
tients with the rs1799983 variant allele is more likely to be an 
acute inflammatory response rather than the conduction re-
covery, because of an earlier timing of ERAF and no increase of 
clinical recurrence after 3 months with the rs1799983 variant al-
lele. The eNOS3 gene variants may have a potential role for de-
termination of post-ablation management such as anti-inflam-
matory drug (e.g., steroid)30 or prediction of clinical outcomes.
Study limitations
We analyzed the SNPs in the eNOS gene in a Korean popula-
tion undergoing catheter ablation. Therefore, our findings can-
not be generalized to all types of AF. When applying SNPs as 
predictors and targets of therapy for AF, possible racial differ-
ences in the association between SNPs and AF should be con-
sidered. Although replication study is needed to validate ge-
netic role, we could not conduct it because of different ablation 
strategies of catheter ablation in the independent cohort.
Conclusion
This study shows that the eNOS3 gene variant, rs1799983, is 
associated with ERAF after catheter ablation, especially at an 
earlier stage within 3 months post-RFCA, but not associated 
with clinical recurrence. Even though we did not find any cor-
relation between eNOS3 gene polymorphism and inflamma-
tory marker, the mechanism of ERAF in patients with the 
rs1799983 variant allele might be associated with an acute in-
flammatory response, and the role of anti-inflammatory medi-
cation should be studied to prevent ERAF in eNOS3 gene vari-
ants at the immediate post-ablation period.
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